Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Lipid Res ; 57(6): 955-68, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-27087439

RESUMEN

Dysfunction of the cerebrovasculature plays an important role in vascular cognitive impairment (VCI). Lipotoxic injury of the systemic endothelium in response to hydrolyzed triglyceride-rich lipoproteins (TGRLs; TGRL lipolysis products) or a high-fat Western diet (WD) suggests similar mechanisms may be present in brain microvascular endothelium. We investigated the hypothesis that TGRL lipolysis products cause lipotoxic injury to brain microvascular endothelium by generating increased mitochondrial superoxide radical generation, upregulation of activating transcription factor 3 (ATF3)-dependent inflammatory pathways, and activation of cellular oxidative stress and apoptotic pathways. Human brain microvascular endothelial cells were treated with human TGRL lipolysis products that induced intracellular lipid droplet formation, mitochondrial superoxide generation, ATF3-dependent transcription of proinflammatory, stress response, and oxidative stress genes, as well as activation of proapoptotic cascades. Male apoE knockout mice were fed a high-fat/high-cholesterol WD for 2 months, and brain microvessels were isolated by laser capture microdissection. ATF3 gene transcription was elevated 8-fold in the hippocampus and cerebellar brain region of the WD-fed animals compared with chow-fed control animals. The microvascular injury phenotypes observed in vitro and in vivo were similar. ATF3 plays an important role in mediating brain microvascular responses to acute and chronic lipotoxic injury and may be an important preventative and therapeutic target for endothelial dysfunction in VCI.


Asunto(s)
Factor de Transcripción Activador 3/genética , Traumatismos Cerebrovasculares/genética , Disfunción Cognitiva/genética , Inflamación/genética , Lipoproteínas/metabolismo , Triglicéridos/metabolismo , Factor de Transcripción Activador 3/biosíntesis , Animales , Cerebelo/irrigación sanguínea , Cerebelo/metabolismo , Cerebelo/patología , Traumatismos Cerebrovasculares/metabolismo , Traumatismos Cerebrovasculares/fisiopatología , Disfunción Cognitiva/metabolismo , Disfunción Cognitiva/fisiopatología , Dieta Alta en Grasa/efectos adversos , Dieta Occidental/efectos adversos , Endotelio Vascular/metabolismo , Endotelio Vascular/fisiopatología , Hipocampo/irrigación sanguínea , Hipocampo/metabolismo , Hipocampo/patología , Humanos , Inflamación/metabolismo , Inflamación/fisiopatología , Ratones , Estrés Oxidativo/genética , Transducción de Señal/genética
2.
J Biol Chem ; 290(32): 19900-9, 2015 Aug 07.
Artículo en Inglés | MEDLINE | ID: mdl-26100626

RESUMEN

Accumulating evidence suggests that activation of mitogen-activated protein kinases (MAPKs) and nuclear factor NF-κB exacerbates early brain injury (EBI) following subarachnoid hemorrhage (SAH) by provoking proapoptotic and proinflammatory cellular signaling. Here we evaluate the role of TGFß-activated kinase 1 (TAK1), a critical regulator of the NF-κB and MAPK pathways, in early brain injury following SAH. Although the expression level of TAK1 did not present significant alternation in the basal temporal lobe after SAH, the expression of phosphorylated TAK1 (Thr-187, p-TAK1) showed a substantial increase 24 h post-SAH. Intracerebroventricular injection of a selective TAK1 inhibitor (10 min post-SAH), 5Z-7-oxozeaenol (OZ), significantly reduced the levels of TAK1 and p-TAK1 at 24 h post-SAH. Involvement of MAPKs and NF-κB signaling pathways was revealed that OZ inhibited SAH-induced phosphorylation of p38 and JNK, the nuclear translocation of NF-κB p65, and degradation of IκBα. Furthermore, OZ administration diminished the SAH-induced apoptosis and EBI. As a result, neurological deficits caused by SAH were reversed. Our findings suggest that TAK1 inhibition confers marked neuroprotection against EBI following SAH. Therefore, TAK1 might be a promising new molecular target for the treatment of SAH.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Traumatismos Cerebrovasculares/prevención & control , Quinasas Quinasa Quinasa PAM/antagonistas & inhibidores , Fármacos Neuroprotectores/farmacología , Inhibidores de Proteínas Quinasas/farmacología , Hemorragia Subaracnoidea/tratamiento farmacológico , Zearalenona/análogos & derivados , Animales , Apoptosis/efectos de los fármacos , Traumatismos Cerebrovasculares/genética , Traumatismos Cerebrovasculares/metabolismo , Traumatismos Cerebrovasculares/patología , Modelos Animales de Enfermedad , Regulación de la Expresión Génica , Proteínas I-kappa B/antagonistas & inhibidores , Proteínas I-kappa B/genética , Proteínas I-kappa B/metabolismo , Inyecciones Intraventriculares , MAP Quinasa Quinasa 4/antagonistas & inhibidores , MAP Quinasa Quinasa 4/genética , MAP Quinasa Quinasa 4/metabolismo , Quinasas Quinasa Quinasa PAM/genética , Quinasas Quinasa Quinasa PAM/metabolismo , Masculino , Inhibidor NF-kappaB alfa , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Neuronas/patología , Fosforilación , Ratas , Ratas Sprague-Dawley , Transducción de Señal , Técnicas Estereotáxicas , Hemorragia Subaracnoidea/genética , Hemorragia Subaracnoidea/metabolismo , Hemorragia Subaracnoidea/patología , Factor de Transcripción ReIA/antagonistas & inhibidores , Factor de Transcripción ReIA/genética , Factor de Transcripción ReIA/metabolismo , Zearalenona/farmacología , Proteínas Quinasas p38 Activadas por Mitógenos/antagonistas & inhibidores , Proteínas Quinasas p38 Activadas por Mitógenos/genética , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA